Search Results

Medtronic plc announced that it has completed the acquisition of Intersect ENT, expanding the company’s comprehensive ear, nose, and throat portfolio with innovative products used in sinus procedures to improve post-operative outcomes and to treat nasal polyps.

Olympus announced the availability of the new DVM-B2 Digital Video Monitor, an all-in-one video processor and monitor for use with single-use endoscopes for both bronchoscopy and ENT including the H-SteriScope™ Single-use Flexible Bronchoscopes and the E-SteriScope™ Single-use Flexible Rhinolaryngoscopes.

Medtronic plc, the global leader in medical technology, announced that it has entered into a definitive agreement with Intersect ENT, a global ear, nose, and throat medical technology leader dedicated to transforming patient care, in which Medtronic will acquire all outstanding shares of Intersect ENT for $28.25 per share in an all-cash transaction implying an enterprise value of approximately $1.1 billion.

Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced positive results of an observational, cohort study using real-world evidence (RWE) data from adult patients with chronic rhinosinusitis (CRS) with or without nasal polyps who underwent endoscopic sinus surgery (ESS).

Intersect ENT, Inc., a global ear, nose and throat medical technology leader dedicated to transforming patient care, reported financial results for the third quarter ended September 30, 2021.

Intersect ENT, Inc., a global ear, nose and throat medical technology leader dedicated to transforming patient care, announced Neil Hattangadi, M.D., M.Sc. joined the Intersect ENT Board of Directors.

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Anthony Vernon has resigned from the Intersect ENT Board of Directors on March 31, 2021.

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that management will participate in the following upcoming investor conferences